Mixed phenotype acute leukemia
Information
- Disease name
- Mixed phenotype acute leukemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03404193 | Active, not recruiting | Phase 2 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | January 18, 2018 | December 31, 2024 |
| NCT02828358 | Active, not recruiting | Phase 2 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | April 1, 2017 | September 22, 2024 |
| NCT05326516 | Active, not recruiting | Phase 1 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | March 9, 2022 | June 2024 |
| NCT05316701 | Active, not recruiting | Phase 3 | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | June 21, 2022 | April 2027 |
| NCT02921061 | Completed | Phase 1/Phase 2 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | November 17, 2016 | October 24, 2018 |
| NCT00723099 | Completed | Phase 2 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | June 25, 2008 | July 31, 2018 |
| NCT02135874 | Completed | Phase 2 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | October 27, 2014 | February 21, 2023 |
| NCT05433532 | Completed | Phase 2 | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | May 1, 2022 | April 13, 2024 |
| NCT06390319 | Not yet recruiting | Phase 2 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | June 2024 | December 2033 |
| NCT06289673 | Not yet recruiting | Phase 4 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | July 2024 | May 2039 |
| NCT05476770 | Recruiting | Phase 1 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | November 11, 2022 | November 11, 2027 |
| NCT05602194 | Recruiting | Phase 3 | Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | August 24, 2023 | December 31, 2027 |
| NCT05735184 | Recruiting | Phase 1 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML | July 18, 2023 | May 2027 |
| NCT06013423 | Recruiting | Phase 2 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | July 6, 2024 | October 31, 2025 |
| NCT03957915 | Recruiting | Early Phase 1 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia | May 29, 2020 | December 28, 2023 |
| NCT03959085 | Recruiting | Phase 3 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | October 31, 2019 | March 31, 2030 |
| NCT04065399 | Recruiting | Phase 1/Phase 2 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | November 5, 2019 | December 2024 |
| NCT04067336 | Recruiting | Phase 1/Phase 2 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | September 12, 2019 | September 30, 2025 |
| NCT04128501 | Recruiting | Phase 2 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | May 5, 2020 | December 31, 2026 |
| NCT04195633 | Recruiting | Phase 2 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | January 25, 2021 | December 31, 2026 |
| NCT04726241 | Recruiting | Phase 1/Phase 2 | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | April 18, 2022 | December 31, 2026 |
| NCT06034470 | Recruiting | Phase 1 | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | December 18, 2023 | December 31, 2027 |
| NCT03779854 | Recruiting | Phase 2 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | August 29, 2019 | December 31, 2025 |
| NCT04872478 | Recruiting | Phase 1 | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL | April 1, 2022 | December 31, 2024 |
| NCT04872790 | Recruiting | Phase 1 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | September 2, 2022 | June 2, 2026 |
| NCT04904588 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | September 30, 2021 | July 2024 |
| NCT03198234 | Recruiting | Phase 1 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders | August 30, 2017 | July 2025 |
| NCT03802695 | Recruiting | Phase 1 | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | April 8, 2019 | April 2028 |
| NCT03843528 | Recruiting | Phase 1 | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | May 1, 2019 | October 30, 2024 |
| NCT05327894 | Recruiting | Phase 3 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | December 15, 2022 | September 2030 |
| NCT03007147 | Recruiting | Phase 3 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | August 8, 2017 | September 30, 2027 |
| NCT05457556 | Recruiting | Phase 3 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | March 15, 2023 | December 1, 2027 |
| NCT03326921 | Suspended | Phase 1 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | February 23, 2018 | July 16, 2028 |
| NCT04797767 | Suspended | Phase 1 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | February 4, 2022 | December 31, 2024 |
| NCT05322850 | Suspended | Phase 1/Phase 2 | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | August 16, 2022 | September 2027 |
| NCT03128034 | Suspended | Phase 1/Phase 2 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | October 24, 2017 | March 31, 2027 |
| NCT01887587 | Terminated | Phase 1 | Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia | June 2013 | February 29, 2016 |
| NCT04762485 | Unknown status | Phase 1/Phase 2 | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia | June 1, 2021 | February 28, 2024 |
| NCT03599869 | Unknown status | Management of Mixed-Phenotype Acute Leukemia in the East of France | September 2018 | June 2019 |